Semaglutide : Approved since 2017 with 7+ years post-marketing data
A 2022 review of semaglutide as a treatment for overweight and obesity recorded an average reduction in body weight of 14.44% in STEP clinical trial participants after 68 weeks of 2.4mg weekly injections
When we initially checked, Grns BBB rating was F due to the company not responding to 25 out of 30 complaints, but later it became NR (Not Rated) because the business is in the process of responding to previously closed complaints. The majority of those aforementioned complaints are about Grns customer service or lack thereof
Thats why whenever we use oral BPC 157, we use the arginate form
Fiorino A, Marturano A, Placella G, Staderini E, Domingo LI, Cerulli GG, Tiribuzi R, Blasi P
Frequently asked questions Which GLP-1 produces the most weight loss on average